Skip to content

Immuno-Oncology Summit Europe 2023

Immuno-Oncology Summit Europe 2023

Immuno-Oncology Summit Europe 2023

Immuno-Oncology Summit Europe 2023

📢 Scailyte is thrilled to announce our attendance at the Immuno-Oncology Summit Europe 2023 in London! 🌟🌍

Scheduled for 20-22 June, this highly anticipated event brings together experts and innovators in the field of immuno-oncology to discuss the latest advancements and breakthrough therapies. We’re proud to be part of this prestigious summit and contribute to the dialogue shaping the future of cancer treatment. 💪💉

Our esteemed team members, Diana Stoycheva (Principal Expert Scientist), Sukalp Muzumdar (Senior Data Scientist), and Filipa Teixeira (Business Development Associate), will be in attendance. We’re particularly excited about Diana’s 30-minute presentation on “Enabling Precision Medicine by Combining Multi-Omics Analysis and Artificial Intelligence” on 21 June at 4:40 PM BST. 🎙️🧬

The Immuno-Oncology Summit Europe features an impressive lineup of keynote speakers, engaging breakout discussions, and a diverse faculty representing both industry and academia. It’s a unique opportunity to connect with peers, exchange ideas, and forge collaborations that can accelerate the development of immunotherapies. 🤝💡

At Scailyte, we’re eager to immerse ourselves in the rich scientific discussions, explore cutting-edge advancements, and network with fellow experts in the immuno-oncology field. Together, we aim to advance the boundaries of precision medicine and revolutionize cancer treatment. 🚀💙

If you’re attending the Immuno-Oncology Summit Europe 2023, we’d love to connect with you! Let’s join forces and shape the future of immuno-oncology together. See you in London! 🗺️🎉

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News

01 /04

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

02 /04

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

03 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

04 /04

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Life Science Industry Meets Data Science Symposium

Scailyte is thrilled to be part of the LIFE SCIENCE INDUSTRY MEETS DATA SCIENCE symposium organised ...

Read more

Recent News